Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Crossref DOI link: https://doi.org/10.1007/s00259-017-3866-2
Published Online: 2017-11-06
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Caroli, Paola
De Giorgi, Ugo
Scarpi, Emanuela
Fantini, Lorenzo
Moretti, Andrea
Galassi, Riccardo
Celli, Monica
Conteduca, Vincenza
Rossi, Lorena
Bianchi, Emanuela
Paganelli, Giovanni
Matteucci, Federica
License valid from 2017-11-06